A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

The hippo signaling pathway in development and cancer. Dev Cell (2010) 10.54

Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01

Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol (1998) 5.15

Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol (2010) 5.05

TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol (2008) 5.02

E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol (1994) 4.34

Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet (2006) 4.23

Antioncogenes and human cancer. Proc Natl Acad Sci U S A (1993) 4.09

ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol (1994) 4.09

Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J Cell Biol (1996) 4.06

Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol (2004) 3.99

Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J Cell Biol (1994) 3.68

The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev (2001) 3.65

Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol (1998) 3.39

Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol Biol Cell (1995) 3.36

Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol (2009) 3.25

Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol (2007) 2.89

Submembranous junctional plaque proteins include potential tumor suppressor molecules. J Cell Biol (1993) 2.87

Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72

Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev (1998) 2.66

Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet (2004) 2.62

Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol (1997) 2.51

Structural basis of the membrane-targeting and unmasking mechanisms of the radixin FERM domain. EMBO J (2000) 2.49

Cloning and characterization of hdlg: the human homologue of the Drosophila discs large tumor suppressor binds to protein 4.1. Proc Natl Acad Sci U S A (1994) 2.41

Rho- and rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts: an essential role for ezrin/radixin/moesin proteins. J Cell Biol (1997) 2.35

Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell (2013) 2.16

Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol (1996) 2.12

Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet (2003) 2.12

Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol (2009) 2.06

Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis (2009) 2.00

Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet (1997) 1.96

Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet (2004) 1.88

The Drosophila tumor suppressors Expanded and Merlin differentially regulate cell cycle exit, apoptosis, and Wingless signaling. Dev Biol (2006) 1.85

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol (2009) 1.78

High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A (1995) 1.76

Drosophila coracle, a member of the protein 4.1 superfamily, has essential structural functions in the septate junctions and developmental functions in embryonic and adult epithelial cells. Mol Biol Cell (1998) 1.71

Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet (1996) 1.70

Structural basis of adhesion-molecule recognition by ERM proteins revealed by the crystal structure of the radixin-ICAM-2 complex. EMBO J (2003) 1.70

Ezrin NH2-terminal domain inhibits the cell extension activity of the COOH-terminal domain. J Cell Biol (1995) 1.63

RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. Mol Biol Cell (1998) 1.62

Germ-line mutational analysis of the TSC2 gene in 90 tuberous-sclerosis patients. Am J Hum Genet (1998) 1.61

The Drosophila lethal(2)giant larvae tumor suppressor protein forms homo-oligomers and is associated with nonmuscle myosin II heavy chain. J Cell Biol (1994) 1.59

Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization. J Cell Biol (1998) 1.58

Distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologues of moesin and the neurofibromatosis 2 tumor suppressor, merlin. J Cell Biol (1996) 1.56

Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet (1996) 1.52

The Drosophila lethal(2)giant larvae tumor suppressor protein is a component of the cytoskeleton. J Cell Biol (1994) 1.48

Merlin is a potent inhibitor of glioma growth. Cancer Res (2008) 1.47

Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet (1998) 1.47

Management of acoustic neuroma. BMJ (1995) 1.44

The kinesin-associated protein UNC-76 is required for axonal transport in the Drosophila nervous system. Mol Biol Cell (2003) 1.43

Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing. Mol Cell Biol (2007) 1.42

Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev (1999) 1.37

Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet (2002) 1.37

Two independent domains of hDlg are sufficient for subcellular targeting: the PDZ1-2 conformational unit and an alternatively spliced domain. J Cell Biol (1996) 1.36

ERM (ezrin/radixin/moesin)-based molecular mechanism of microvillar breakdown at an early stage of apoptosis. J Cell Biol (1997) 1.35

Molecular dissection of radixin: distinct and interdependent functions of the amino- and carboxy-terminal domains. J Cell Biol (1995) 1.34

Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A (2004) 1.34

NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. J Cell Biol (2011) 1.34

A conserved functional domain of Drosophila coracle is required for localization at the septate junction and has membrane-organizing activity. J Cell Biol (1998) 1.33

Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol (1995) 1.32

Biochemical and molecular characterization of the chicken cysteine-rich protein, a developmentally regulated LIM-domain protein that is associated with the actin cytoskeleton. J Cell Biol (1994) 1.31

Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data. Genome Biol (2003) 1.31

Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep (2012) 1.30

Listeria monocytogenes exploits ERM protein functions to efficiently spread from cell to cell. EMBO J (2005) 1.28

Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol (1999) 1.26

Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol (2013) 1.26

Suppression of breast cancer cell growth by Na+/H+ exchanger regulatory factor 1 (NHERF1). Breast Cancer Res (2006) 1.26

Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Neurol Neurosurg Psychiatry (1997) 1.26

EPB41L5 functions to post-transcriptionally regulate cadherin and integrin during epithelial-mesenchymal transition. J Cell Biol (2008) 1.24

Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction. Mol Med (1998) 1.24

Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A (2011) 1.24

Neurofibromatosis type 2. J Med Genet (2000) 1.22

Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci (2010) 1.21

The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. Proc Natl Acad Sci U S A (2007) 1.17

Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet (1994) 1.17

Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins. Mol Cell Biol (2000) 1.16

A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet (1994) 1.15

The multiple functions of TRBP, at the hub of cell responses to viruses, stress, and cancer. Microbiol Mol Biol Rev (2012) 1.14

Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells. Breast Cancer Res (2008) 1.14

Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry (2004) 1.13

Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function. Proc Natl Acad Sci U S A (2011) 1.13

Our changing view of the genomic landscape of cancer. J Pathol (2010) 1.13

Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet (1994) 1.13

Three determinants in ezrin are responsible for cell extension activity. Mol Biol Cell (1997) 1.12

Drosophila cancer models. Dev Dyn (2011) 1.10

Efficient selection of 3'-terminal exons from vertebrate DNA. Nucleic Acids Res (1993) 1.10

Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway. Cell Res (2015) 1.09

An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway. Mol Cell Biol (1994) 1.07

Phosphorylation and activity of the tumor suppressor Merlin and the ERM protein Moesin are coordinately regulated by the Slik kinase. J Cell Biol (2006) 1.07

Loss of heterozygosity on long arm of chromosome 22 in sporadic colorectal carcinoma. World J Gastroenterol (2002) 1.07

Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol (2001) 1.07

Adhesion systems in normal breast and in invasive breast carcinoma. Am J Pathol (1995) 1.06

Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet (2004) 1.05

The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol (2002) 1.04

Genotype, malleotype, phenotype, and randomness: lessons from neurofibromatosis-1 (NF-1) Am J Hum Genet (1993) 1.03

Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. BMC Med Genomics (2009) 1.03

AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol (2011) 1.02

Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol (1997) 1.02

The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol (2008) 1.01

The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol Neurotol (2008) 1.01

Segmental aneuploidy and the genetic gross structure of the Drosophila genome. Genetics (1972) 22.68

Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13

Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control (2001) 4.74

Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76

Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet (1997) 3.64

Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell (1987) 3.60

Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature (1995) 3.55

Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat (1996) 2.80

The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell (1998) 2.77

Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology (1980) 2.77

The distribution and differentiation of lymph-borne immunoblasts after intravenous injection into syngeneic recipients. Cell Tissue Kinet (1972) 2.52

Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology (1983) 2.47

Isolation of genes from complex sources of mammalian genomic DNA using exon amplification. Nat Genet (1994) 2.33

NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med (1990) 2.31

Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum Mol Genet (1999) 2.20

A meiotic mutant affecting recombination in female Drosophila melanogaster. Genetics (1973) 2.17

Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med (1988) 2.16

Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet (1998) 2.13

Interstitial collagenases as markers of tumor progression. Clin Cancer Res (2000) 2.13

Linkage analysis of neurofibromatosis (von Recklinghausen disease). J Med Genet (1983) 2.13

Multipoint linkage analysis in neurofibromatosis type I: an international collaboration. Am J Hum Genet (1989) 2.04

De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat Genet (1993) 2.02

Von Hippel-Lindau disease: clinical and pathological manifestations in nine families with 50 affected members. Arch Intern Med (1976) 1.97

Gilles de la Tourette's syndrome: clinical, genetic, psychologic, and biochemical aspects in 21 selected families. Neurology (1977) 1.97

Attitudes of patients and their relatives to Huntington's disease. J Med Genet (1975) 1.96

The torsion dystonias: literature review and genetic and clinical studies. Neurology (1970) 1.91

PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene (1999) 1.89

Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci U S A (1997) 1.89

Salivary acinar cells from aquaporin 5-deficient mice have decreased membrane water permeability and altered cell volume regulation. J Biol Chem (2001) 1.88

Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet (1994) 1.84

Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res (1997) 1.83

Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem (1995) 1.79

Relationship between head circumference and height in normal adults and in the nevoid basal cell carcinoma syndrome and neurofibromatosis type I. Am J Med Genet (1991) 1.77

High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A (1995) 1.76

Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. Proc Natl Acad Sci U S A (1999) 1.73

Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Mol Genet (1994) 1.66

Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet (1994) 1.63

Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet (1994) 1.62

A novel member of the netrin family, beta-netrin, shares homology with the beta chain of laminin: identification, expression, and functional characterization. J Cell Biol (2000) 1.59

The genetic identification of a heterochromatic segment on the X chromosome of Drosophila melanogaster. Genetics (1974) 1.59

Gilles de la Tourette syndrome: clinical and family study of 50 cases. Ann Neurol (1980) 1.59

Pharmacogenomics, ethnicity, and susceptibility genes. Pharmacogenomics J (2001) 1.56

Retinal degeneration but not obesity is observed in null mutants of the tubby-like protein 1 gene. Hum Mol Genet (2000) 1.55

Vestibular schwannoma (acoustic neuroma). Consensus development conference. Neurosurgery (1992) 1.55

Physical mapping of the von Recklinghausen neurofibromatosis region on chromosome 17. Am J Hum Genet (1989) 1.54

Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet (1996) 1.52

Characterization of flavonol synthase and leucoanthocyanidin dioxygenase genes in Arabidopsis. Further evidence for differential regulation of "early" and "late" genes. Plant Physiol (1997) 1.49

Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol (1999) 1.49

Electron microscope autoradiography of erythroid cells using radioactive iron. J Cell Biol (1973) 1.48

Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat Genet (1993) 1.48

Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology (2010) 1.46

Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma. Oncogene (1995) 1.44

Decreased expression of aquaporin (AQP)1 and AQP5 in mouse lung after acute viral infection. Am J Respir Cell Mol Biol (2000) 1.44

Molecular genetics of Huntington's disease. Arch Neurol (1993) 1.40

Tau pathology in a family with dementia and a P301L mutation in tau. J Neuropathol Exp Neurol (1999) 1.38

A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell (1993) 1.38

Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology (2001) 1.37

Definition of dystonia and classification of the dystonic states. Adv Neurol (1976) 1.36

Aquaporin 5-deficient mouse lungs are hyperresponsive to cholinergic stimulation. Proc Natl Acad Sci U S A (2001) 1.35

Central neurofibromatosis with bilateral acoustic neuroma. Adv Neurol (1981) 1.34

The association of posterior capsular lens opacities with bilateral acoustic neuromas in patients with neurofibromatosis type 2. Arch Ophthalmol (1989) 1.34

Familial motor neuron disease. Evidence for at least three different types. Neurology (1976) 1.34

Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res (1995) 1.33

Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol (1995) 1.32

Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res (1994) 1.29

Superior intelligence in recessively inherited torsion dystonia. Lancet (1970) 1.28

Physical mapping of a translocation breakpoint in neurofibromatosis. Science (1989) 1.27

Multiple sclerosis in twins. Neurology (1980) 1.26

Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology (2002) 1.25

Manganese superoxide dismutase signals matrix metalloproteinase expression via H2O2-dependent ERK1/2 activation. J Biol Chem (2001) 1.23

A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen. J Biol Chem (1999) 1.22

Eye findings in bilateral acoustic (central) neurofibromatosis: association with presenile lens opacities and cataracts but absence of Lisch nodules. N Engl J Med (1986) 1.21

Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene (1999) 1.20

Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res (1994) 1.20

Primitive roles for inhibitory interneurons in developing frog spinal cord. J Neurosci (2004) 1.20

Intracellular localization and properties of particulate hexokinase in the Novikoff ascites tumor. Evidence for an outer mitochondrial membrane location. J Biol Chem (1983) 1.20

Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. Proc Natl Acad Sci U S A (1987) 1.20

Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res (1991) 1.19

Familial chordoma, a tumor of notochordal remnants, is linked to chromosome 7q33. Am J Hum Genet (2001) 1.19

High percentage of false positive cardiac troponin I results in patients with rheumatoid factor. Clin Biochem (1999) 1.18

The low concordance rate for Parkinson's disease in twins: a possible explanation. Neurology (1984) 1.18

Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet (1994) 1.17

A new method for analyzing electron microscope autoradiographs using hypothetical grain distributions. J Cell Biol (1973) 1.17

Survival after retinoblastoma: long-term consequences and family history of cancer. Med Pediatr Oncol (1995) 1.16

Gametic but not somatic instability of CAG repeat length in Huntington's disease. J Med Genet (1993) 1.15

p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J Biol Chem (1999) 1.15